5-Jun-2026
Market Chameleon (Fri, 8-May 6:33 AM ET)
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Fri, 27-Mar 7:00 AM ET)
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Werewolf Therapeutics trades on the NASDAQ stock market under the symbol HOWL.
As of June 5, 2026, HOWL stock price declined to $0.39 with 576,666 million shares trading.
HOWL has a beta of 1.67, meaning it tends to be more sensitive to market movements. HOWL has a correlation of 0.04 to the broad based SPY ETF.
HOWL has a market cap of $19.06 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, HOWL traded as high as $8.19 and as low as $.39.
The top ETF exchange traded funds that HOWL belongs to (by Net Assets): VTI, VXF.
HOWL has underperformed the market in the last year with a price return of -68.1% while the SPY ETF gained +25.6%. HOWL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.9% and -11.6%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
HOWL support price is $.40 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOWL shares will trade within this expected range on the day.